Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Cell/Gene Tx channel feed
Updated: Jim Wilson to step down from gene therapy post at UPenn, will form two new companies
11 months ago
People
R&D
Umoja to dose first patient with in vivo CAR-T by end of this year
11 months ago
R&D
Manufacturing
Exclusive: Myeloid Therapeutics moves second in vivo cell therapy into trials, targeting liver cancer
11 months ago
R&D
Pfizer cuts 210 North Carolina workers after it officially discontinues failed Duchenne gene therapy
11 months ago
People
Manufacturing
Artiva's IPO raises $167M to fund company's autoimmune and cancer cell therapies
11 months ago
Financing
Startups
4DMT builds out case for wet AMD gene therapy with new Phase 2 data
11 months ago
R&D
Adverum prepares pivotal study for wet AMD gene therapy, touts Phase 2 data
11 months ago
R&D
Caribou to slash preclinical allogeneic CAR-NK work, lay off 12% of staff
11 months ago
People
R&D
After last year's ImmunoGen pact, Vertex finds another conditioning agent partner in Orum
11 months ago
Startups
Deals
Updated: Lexeo Therapeutics' gene therapy shows potential for Friedreich's ataxia cardiomyopathy with early data
12 months ago
R&D
Artiva aims for $116M in second attempt at IPO to boost NK cell therapy pipeline
12 months ago
Financing
Roche's gene therapy biotech Spark is laying off employees, ending some early-stage programs
12 months ago
People
UniQure trumpets mid-stage data for Huntington's disease gene therapy
Last year
R&D
Infections are major cause of non-relapse deaths after CAR-T cell therapy, study shows
Last year
R&D
Exclusive: Gene insertion startup launches with new integrase technology from University of Hawaii
Last year
Financing
Startups
Beacon raises $170M to take on J&J in ocular gene therapy
Last year
Financing
Startups
J&J and Legend say Carvykti improved survival in earlier-line multiple myeloma
Last year
R&D
Cartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M
Last year
Financing
R&D
FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing
Last year
FDA+
Manufacturing
Lyell reports patient death, early responses in solid tumor CAR-T trial
Last year
R&D
Can CRISPR be given twice? Small study from Intellia suggests it can
Last year
R&D
Can mRNA be harnessed for gene insertion? Moderna's former chief medical officer has $82M to find out
Last year
Financing
Startups
Fractyl pitches potential of GLP-1 gene therapy, but pushes clinical trials back to 2025
Last year
R&D
Peter Marks single-handedly approved Sarepta’s gene therapy — what does that mean for everyone else?
Last year
Pharma
FDA+
First page
Previous page
5
6
7
8
9
10
11
Next page
Last page